Trial · NCT03805100
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Best Corrected Visual Acuity (BCVA) | Xlucane (Proposed Ranibizumab Biosimilar) | 4.57 | 95% Confidence Interval 3.54 to 5.61 | Letters | |
| Change in Best Corrected Visual Acuity (BCVA) | Lucentis (Ranibizumab) | 6.37 | 95% Confidence Interval 5.31 to 7.42 | Letters | |
| Change From Baseline in the Total Size of Choroidal Neovascular Leakage Area in the Study Eye | Xlucane (Proposed Ranibizumab Biosimilar) | -4.09 | 95% Confidence Interval -4.66 to -3.52 | mm2 | |
| Change From Baseline in the Total Size of Choroidal Neovascular Leakage Area in the Study Eye | Lucentis (Ranibizumab) | -3.71 | 95% Confidence Interval -4.28 to -3.14 | mm2 | |
| Change From Baseline in the Total Size of Choroidal Neovascularisation in the Study Eye | Xlucane (Proposed Ranibizumab Biosimilar) | -1.62 | 95% Confidence Interval -2.19 to -1.05 | mm2 | |
| Change From Baseline in the Total Size of Choroidal Neovascularisation in the Study Eye | Lucentis (Ranibizumab) | -1.11 | 95% Confidence Interval -1.68 to -0.54 | mm2 | |
| Central Foveal Thickness in the Study Eye | Xlucane (Proposed Ranibizumab Biosimilar) | -117.44 | 95% Confidence Interval -125.33 to 109.55 | um | |
| Central Foveal Thickness in the Study Eye | Lucentis (Ranibizumab) | -115.14 | 95% Confidence Interval -123.14 to -107.14 | um | |
| Percentage of Subjects With Loss of <15 BCVA Letters | Xlucane (Proposed Ranibizumab Biosimilar) | Missing at random (MAR) | 94.8 | percentage of responders | |
| Percentage of Subjects With Loss of <15 BCVA Letters | Lucentis (Ranibizumab) | Missing at random (MAR) | 96.0 | percentage of responders | |
| Percentage of Subjects With Loss of <15 BCVA Letters | Xlucane (Proposed Ranibizumab Biosimilar) | Missing completely at random (MCAR) | 94.9 | percentage of responders | |
| Percentage of Subjects With Loss of <15 BCVA Letters | Lucentis (Ranibizumab) | Missing completely at random (MCAR) | 96.1 | percentage of responders | |
| Percentage of Subjects With Loss of <15 BCVA Letters | Xlucane (Proposed Ranibizumab Biosimilar) | Missing not at random (MNAR) | 94.8 | percentage of responders | |
| Percentage of Subjects With Loss of <15 BCVA Letters | Lucentis (Ranibizumab) | Missing not at random (MNAR) | 96.1 | percentage of responders | |
| Percentage of Subjects With Loss of <15 BCVA Letters | Xlucane (Proposed Ranibizumab Biosimilar) | Composite (Missing and non-evaluable data are classed as no response) | 68.8 | percentage of responders | |
| Percentage of Subjects With Loss of <15 BCVA Letters | Lucentis (Ranibizumab) | Composite (Missing and non-evaluable data are classed as no response) | 67.6 | percentage of responders | |
| Percentage of Subjects With Gain of ≥15 BCVA Letters | Xlucane (Proposed Ranibizumab Biosimilar) | Missing at random (MAR) | 23.6 | percentage of responders | |
| Percentage of Subjects With Gain of ≥15 BCVA Letters | Lucentis (Ranibizumab) | Missing at random (MAR) | 29.7 | percentage of responders | |
| Percentage of Subjects With Gain of ≥15 BCVA Letters | Xlucane (Proposed Ranibizumab Biosimilar) | Missing completely at random (MCAR) | 23.2 | percentage of responders | |
| Percentage of Subjects With Gain of ≥15 BCVA Letters | Lucentis (Ranibizumab) | Missing completely at random (MCAR) | 28.8 | percentage of responders |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03805100/results